Macrogenics (FRA:M55) Float Percentage Of Total Shares Outstanding: 96.48% (As of Jul. 09, 2026)


FRA:M55 Macrogenics Inc FRA:M55
47 GF Score
Price €4.12
GF Value €3.59
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Macrogenics Float Percentage Of Total Shares Outstanding?

Macrogenics FRA:M55 +4.04% 47 Float Percentage Of Total Shares Outstanding is 96.48% as of Jul. 09, 2026. GuruFocus rates FRA:M55 with a GF Score™ of 47/100 and a GF Value™ of €3.59 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Macrogenics's float shares is 61.32 Mil. Macrogenics's total shares outstanding is 63.56 Mil. Macrogenics's float percentage of total shares outstanding is 96.48%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Macrogenics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Macrogenics's Institutional Ownership is 35.83%.

FRA:M55
47GF Score
Macrogenics Inc FRA:M55
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Macrogenics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Macrogenics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=61.32/63.56
=96.48%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 96.48% mean?
Macrogenics (FRA:M55) has a Float Percentage Of Total Shares Outstanding of 96.48% as of Jul. 09, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Macrogenics and its competitors.
Is Macrogenics' Float Percentage Of Total Shares Outstanding too high?
Macrogenics' current Float Percentage Of Total Shares Outstanding is 96.48%. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Float Percentage Of Total Shares Outstanding compare to IMRX and TRDA?
Macrogenics' Float Percentage Of Total Shares Outstanding of 96.48% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Macrogenics and its competitors. Macrogenics's current Float Percentage Of Total Shares Outstanding is 96.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €4.12 — trading 14.8% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 96.48%. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Float Percentage Of Total Shares Outstanding is 96.48% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €4.12 is trading 14.8% above its estimated GF Value™ of €3.59. GuruFocus considers Macrogenics to be Modestly Overvalued.

Key valuation signals for FRA:M55:

  • Float Percentage Of Total Shares Outstanding: 96.48%
  • GF Value™: €3.59 vs. price of €4.12 (14.8% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score

Get the complete analysis for FRA:M55

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.12
Price
€3.59
GF Value